Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI steps in to catch complications rheumatoid arthritis patients often miss

NCT ID NCT07301892

Diagnosis Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a generative AI tool can help doctors diagnose complications and co-existing diseases in people with rheumatoid arthritis. The AI reviews patient records and suggests possible issues like lung or heart problems. Doctors then decide if the AI's suggestions are useful. The goal is to see if AI can improve diagnosis without replacing the doctor's judgment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Generative AI prediction report
What this could lead to
If successful, this AI tool could help doctors catch hidden complications of rheumatoid arthritis earlier, leading to more complete diagnoses.
What could go wrong
This is an early feasibility study with only 100 participants. The AI predictions may not always be accurate or useful in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male and female RA inpatients admitted to our Rheumatology Department who fulfill the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification and diagnostic criteria for rheumatoid arthritis.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with an initial diagnosis of rheumatoid arthritis (RA). * All real-world RA inpatients admitted to our department. * Admission occurring within the real-world data study period. Exclusion Criteria: * Patients subsequently confirmed not to have RA during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyloidosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amyloidosis cardiovascular disorder Digestive System Diseases interstitial lung disease kidney disorder liver disorder osteoarthritis osteoporosis peripheral nervous system disorder peripheral neuropathy rheumatoid arthritis Sjogren syndrome thrombotic disease thyroid gland disorder vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyloidosis Cardiovascular diseases Interstitial lung disease Liver disorders Osteoarthritis Osteoporosis Peripheral neuropathy Pulmonary complications RA complications Renal lesions Rheumatoid arthritis (RA Sjogren's syndrome Thrombosis Thyroid diseases Vasculitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.